{
  "id": 3548090,
  "title": "Biohaven strikes $795M deal for commercial partner in epilepsy",
  "url": "https://urgent.news/2026/08/26/biohaven-strikes-795m-deal-for-commercial-partner-in-epilepsy",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-26T17:07:48.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/biohaven-strikes-795m-deal-for-commercial-partner-in-epilepsy/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Biohaven has found a commercial partner for its late-stage epilepsy drug. South Korea-based SK Biopharmaceuticals has offered up to $795 million for the global rights to Biohaven’s Kv7 ion channel platform, including its lead candidate ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}